Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4602 in Advanced Solid Tumors
NCT06704828Phase 2Not yet recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Primary completion
- Apr 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4602 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
SHR-4602
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06704828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704828.